Anteris Technologies Global (NASDAQ:AVR) Major Shareholder L1 Capital Pty Ltd Buys 5,000,000 Shares

Anteris Technologies Global Corp. (NASDAQ:AVR) major shareholder L1 Capital Pty Ltd acquired 5,000,000 shares of the firm’s stock in a transaction that occurred on Thursday, January 22nd. The shares were bought at an average price of $5.75 per share, with a total value of $28,750,000.00. Following the acquisition, the insider directly owned 13,219,814 shares in the company, valued at $76,013,930.50. This represents a 60.83% increase in their ownership of the stock. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Major shareholders that own more than 10% of a company’s stock are required to disclose their transactions with the SEC.

Anteris Technologies Global Trading Up 2.2%

AVR opened at $5.61 on Tuesday. The company has a quick ratio of 0.80, a current ratio of 0.84 and a debt-to-equity ratio of 0.01. The stock’s fifty day moving average is $5.25 and its two-hundred day moving average is $4.61. The company has a market capitalization of $231.13 million, a P/E ratio of -3.10 and a beta of 1.29. Anteris Technologies Global Corp. has a 52 week low of $2.34 and a 52 week high of $8.79.

Anteris Technologies Global (NASDAQ:AVR) last posted its quarterly earnings results on Wednesday, November 12th. The company reported ($0.62) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.57) by ($0.05). The firm had revenue of $0.43 million for the quarter, compared to the consensus estimate of $0.74 million. Anteris Technologies Global had a negative return on equity of 252.71% and a negative net margin of 3,944.93%. Analysts forecast that Anteris Technologies Global Corp. will post -2.66 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the stock. Weiss Ratings reissued a “sell (e+)” rating on shares of Anteris Technologies Global in a report on Monday, December 29th. Lake Street Capital reaffirmed a “buy” rating and set a $15.00 target price on shares of Anteris Technologies Global in a research report on Friday, January 23rd. One research analyst has rated the stock with a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $15.00.

Institutional Trading of Anteris Technologies Global

Institutional investors have recently made changes to their positions in the business. L1 Capital Pty Ltd increased its position in Anteris Technologies Global by 143.2% during the 3rd quarter. L1 Capital Pty Ltd now owns 6,838,136 shares of the company’s stock valued at $30,772,000 after buying an additional 4,026,136 shares in the last quarter. Nantahala Capital Management LLC grew its stake in shares of Anteris Technologies Global by 13.3% during the third quarter. Nantahala Capital Management LLC now owns 1,918,666 shares of the company’s stock worth $8,634,000 after acquiring an additional 225,000 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in shares of Anteris Technologies Global by 32.7% during the third quarter. JPMorgan Chase & Co. now owns 1,417,627 shares of the company’s stock valued at $6,379,000 after acquiring an additional 349,299 shares in the last quarter. Geode Capital Management LLC raised its position in shares of Anteris Technologies Global by 6.3% in the 4th quarter. Geode Capital Management LLC now owns 796,069 shares of the company’s stock valued at $3,973,000 after purchasing an additional 47,119 shares during the last quarter. Finally, Vanguard Group Inc. raised its position in shares of Anteris Technologies Global by 85.1% in the 3rd quarter. Vanguard Group Inc. now owns 745,560 shares of the company’s stock valued at $3,355,000 after purchasing an additional 342,711 shares during the last quarter.

Anteris Technologies Global Company Profile

Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.